Oncortarget Purposes to put an end to Cancer by publishing important information

Oncortarget is an American based peer-reviewed access journal which contains medical articles on oncology. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Oncology, therefore, deals with functions of the cells common in aging and cancer. Oncortarget publishes subsections on topics such as Aging, Immunology, Microbiology among others and the access to this information is free Research of cancerous tumors is been done to get information on how to manage and treat the malignant cells during the early stages. Check the journal at SCImago Journal & Country Rank.

The oncortarget journal is published once per week as this information is of importance as most people are succumbing to cancer. The information published on Oncortarget is on the pervasiveness of the disease and its primary causes, the treatments available and future possible ways to control and possibly eliminate it. The scientists who publish this journal are those who have vast knowledge and are highly skilled in the different roles they play.

The oncortarget mission is to make the scientific findings available to a large number of people at the shortest time possible; bringing together diverse specialists and linking different sectors of medical research and researchers along with their various discoveries. To be able to serve all who needs the information, Oncortarget makes sure that two free issues are available to the public on Tuesdays and Fridays. Follow Oncotarget journal on Twitter.

To further increase the reach and influence of scientific information, the papers which are accepted are later published in PubMed. Recently, Oncortarget published research conducted involving the Alzheimer’s disease and diabetes. The research findings were that those people with Alzheimer’s disease have a higher risk of diagnosis with type 2 diabetes in future.

On 19th September this year, Oncortarget reassured its readers that its publications would continue to be available on PubMed. In partnership with National Library of Medicine, Oncortarget has become the first scientific journal to submit its issues to PubMed days after it publishes the information online. Oncortarget aims at eliminating this 21 century ‘killer’ and targets to see a life without disease.

Read: https://www.eurekalert.org/pub_releases/2017-10/cg-e-s101817.php

The Great Achievements of Clay Siegall

Clay has proved to be a great leader and being the founder and CEO of Seattle Genetics; he has in the recent years led the company towards its great successes. Clay has seen Seattle Genetics rise from a small firm into a prestigious and well-established company. The company which he founded in 1998 has brought significant revolutions in the healthcare sector through its employee’s great innovations. The firm has in the recent years focused on the invention and manufacture of therapeutic drugs to address the various diseases and conditions in humans that have not seen substantial mortality improvements in the past years.

The fast growth of the firm is proving of Clay`s impeccable skills as well as commitment towards achieving the best. The renowned CEO has also always paid attention to his team of employees as through their insight; he gets to acquire developmental ideas to aid in the operation of the firm. Clay has had many achievements in his career, and the development of an FDA approved antibody marked one of the lifetime achievements of the Seattle Genetics firm. The antibody currently acquired multiple approved indications, and this has seen Clay gain an excellent reputation for his significant contributions to the health sector.

Clay has proved to possess impeccable as well as excellent leadership skills, which has, in turn, motivated his team of employees. Under his instruction, the firm has successfully built a diverse pipeline of antibody-based cancer therapies which have eased the considerable effects of the deadly disease to its victims. Clay Siegall has always considered innovation as part of his business operations and throughout his career, he strives to come up with creative ideas that he believes will come to the aid of all the people suffering from severe diseases that cause them strain or acute stress. Besides Clay is a hard believer in teamwork and since the establishment of his firm, he has seen it collaborate with other companies to increase its production through the implementation of the ideas that they acquire from the other groups. Among the firms that Seattle Genetics has entered into multiple strategic licenses include, AbbVie, Genentech, Pfizer and many more.